Supplementary Figures – Developing an immune signature for triple‑negative breast cancer to predict prognosis and immune checkpoint inhibitor
Supplementary Figure S1. Developing an immune signature for triple‑negative breast cancer to predict prognosis and immune checkpoint inhibitor Flow diagram of the study
Supplementary Figure S2. Developing an immune signature for triple‑negative breast cancer to predict prognosis and immune checkpoint inhibitor (A) Kaplan-Meier curve of progression-free survival in training set; (B) Kaplan-Meier curve of metastasisfree survival in validation set
Supplementary Figure S3. Developing an immune signature for triple‑negative breast cancer to predict prognosis and immune checkpoint inhibitor (A) The summary of the overall mutation profile in training set; (B) Mutation profile in training set
Supplementary Figure S4. Developing an immune signature for triple‑negative breast cancer to predict prognosis and immune checkpoint inhibitor Bar chart of the relative proportion of the 22 immune cells in each patient in training set
Supplementary Figure S5. Developing an immune signature for triple‑negative breast cancer to predict prognosis and immune checkpoint inhibitor (A) Bar chart of the relative proportion of the 22 immune cells in each patient in validation set; (B) The difference of proportions of 21 immune infiltration cells in high-risk and low-risk group in validation set
Supplementary Figure S6. Developing an immune signature for triple‑negative breast cancer to predict prognosis and immune checkpoint inhibitor (A)Immune score between high-risk and low-risk group in validation set; (B) Stromal score between highrisk and low-risk group in validation set;(C) PD-1 expression between high-risk and low-risk group in validation set; (D)
|